|
The company has two investigational new drug (IND) applications approved by FDA.
One IND allows human trial for the treatment of erectile dysfunction.
A phase 1a and 1b trial in 20 men has been completed.
The second application was assigned IND 13208 by FDA on January 10, 2007 by FDA. This trial entitled, "A phase I multicenter study evaluating the safety and potential activity of three escalating doses of hMaxi-K gene transfer in female participants with overactive bladder syndrome and detrusor overactivity: double blind, imbalance placebo controlled design within 3 sequential active treatments groups" is now over.
The trial was being managed by the CRO, CE3 of Branford, CT.
|
